Patent · US Active

Nucleic acids for inhibiting expression of LPA in a cell

US12054717B2 · kind B2 · utility

0Cited by

2References

17Claims

0Family size

Assignee

Sapience Therapeutics, Inc. · DE

Inventors

Sibylle Dames · Berlin, DE
Steffen Schubert · Berlin, DE
Stephan Tenbaum · Biberach an der Riß, DE
Christian Frauendorf · Berlin, DE
Lucas Bethge · Potsdam, DE
Judith Hauptmann · Berlin, DE
Adrien Weingärtner · Berlin, DE

Key dates

Filing date	Mar 17, 2022
Grant date	Aug 6, 2024
Priority date	—
Expiry date	Mar 17, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/351
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.